EUVIMEDEUVIMED entdecken
Open Access

Restricting Placental Transfer of Angiotensin Receptor Blockers to Mitigate Fetal Toxicity: A Potential Therapeutic Strategy for Preeclampsia

Naoko Inaoka iD, Takayuki Iriyama iD, Yu Ariyoshi, Yuri Yoshida, Seisuke Sayama, Eriko Yano iD, Haruka Matsui, Kensuke Suzuki, Mari Ichinose, Kenbun Sone iD, Keiichi Kumasawa iD, Osamu Wada-Hiraike iD und 12 weitere

Journal of the American Heart Association · 20.10.2026 · 15 (20)

DOI: 10.1161/jaha.126.050607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 20.10.2026. Verfasst von Naoko Inaoka und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Graduate School of Medicine The University of Tokyo Tokyo Japan. Hauptthemen laut MEDLINE: Pre-Eclampsia, Angiotensin II Type 1 Receptor Blockers, Placenta, Tetrazoles. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enhanced AT 1 R (angiotensin II type 1 receptor) signaling contributes to preeclampsia development; however, angiotensin receptor blockers are contraindicated during pregnancy because of associated fetal toxicity. We aimed to determine whether chemical modification of an angiotensin receptor blocker restricts placental transfer while preserving maternal pharmacological activity.

Methods

Polyethylene glycol‐modified olmesartan derivatives were synthesized to increase molecular size and hydrophilicity and evaluated in vitro for AT 1 R inhibitory activity. Placental transfer was assessed using an angiotensin II‐induced pregnant mouse model and an ex vivo human placental perfusion model to identify a derivative with reduced placental permeability. The selected compound was evaluated in vivo for pharmacological activity and fetal toxicity in pregnant mice.

Results

A series of polyethylene glycol‐modified olmesartan derivatives maintained pharmacologically relevant AT 1 R inhibitory activity in vitro. Evaluation in angiotensin II‐treated pregnant mice revealed compound #6, a polyethylene glycol‐modified dimer containing an ionizable tertiary amine, which exhibited reduced placental transfer (∼7% relative to olmesartan). Consistently, compound #6 exhibited minimal transplacental transfer in the human placental perfusion model, comparable to insulin, a negative control. Regarding fetal toxicity, olmesartan induced neonatal renal developmental toxicity at doses as low as one tenth of its minimum effective dose, whereas compound #6 exhibited clear renal toxicity only above its effective dose, indicating a discernible safety margin.

Conclusions

Restricting placental transfer through rational chemical modification enables decoupling of maternal efficacy from fetal toxicity of angiotensin receptor blockers. Although further optimization is required, these findings provide proof of concept that AT 1 R inhibition may represent a therapeutic strategy for preeclampsia during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaAngiotensin II Type 1 Receptor BlockersPlacentaTetrazolesImidazolesMaternal-Fetal ExchangeFemaleAnimalsPregnancyHumansPolyethylene GlycolsMiceReceptor, Angiotensin, Type 1Disease Models, AnimalMice, Inbred C57BL

Stichwörter der Autor:innen

angiotensin II type 1 receptorangiotensin receptor blockersdrug developmentplacental transferpreeclampsia

Substanzen

Angiotensin II Type 1 Receptor BlockersTetrazolesImidazolesolmesartanPolyethylene GlycolsReceptor, Angiotensin, Type 1

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Graduate School of Medicine The University of Tokyo Tokyo Japan.
  • Department of Obstetrics and Gynecology International University of Health and Welfare Chiba Japan.
  • Laboratory of Veterinary Pathology Osaka Metropolitan University Osaka Japan.
  • Lead Exploration Unit, Drug Discovery Initiative, Graduate School of Pharmaceutical Sciences The University of Tokyo Tokyo Japan.

ORCID-Profile: Naoko Inaoka, Takayuki Iriyama, Eriko Yano, Kenbun Sone, Keiichi Kumasawa, Osamu Wada-Hiraike, Takeshi Nagamatsu, Takeshi Izawa, Jyoji Yamate, Mayumi Ishii, Kosuke Yasuda, Yasushi Hirota

Zitieren

APA

Inaoka, N., Iriyama, T., Ariyoshi, Y., Yoshida, Y., Sayama, S., Yano, E., Matsui, H., Suzuki, K., Ichinose, M., Sone, K., Kumasawa, K., Wada-Hiraike, O., Nagamatsu, T., Fumimoto, T., Izawa, T., Yamate, J., Watanabe, E., Nishikawa, T., Ishii, M., …, & Hirota, Y. (2026). Restricting Placental Transfer of Angiotensin Receptor Blockers to Mitigate Fetal Toxicity: A Potential Therapeutic Strategy for Preeclampsia. Journal of the American Heart Association, 15(20). https://doi.org/10.1161/jaha.126.050607

Vancouver

Inaoka N, Iriyama T, Ariyoshi Y, Yoshida Y, Sayama S, Yano E, et al. Restricting Placental Transfer of Angiotensin Receptor Blockers to Mitigate Fetal Toxicity: A Potential Therapeutic Strategy for Preeclampsia. Journal of the American Heart Association. 2026;15(20). doi:10.1161/jaha.126.050607

BibTeX
@article{Inaoka2026,
  author = {Inaoka, Naoko and Iriyama, Takayuki and Ariyoshi, Yu and Yoshida, Yuri and Sayama, Seisuke and Yano, Eriko and Matsui, Haruka and Suzuki, Kensuke and Ichinose, Mari and Sone, Kenbun and Kumasawa, Keiichi and Wada-Hiraike, Osamu and Nagamatsu, Takeshi and Fumimoto, Tamiko and Izawa, Takeshi and Yamate, Jyoji and Watanabe, Eri and Nishikawa, Tomoyuki and Ishii, Mayumi and Kanamitsu, Kayoko and Iijima, Toru and Suto, Naoki and Yasuda, Kosuke and Hirota, Yasushi},
  title = {Restricting Placental Transfer of Angiotensin Receptor Blockers to Mitigate Fetal Toxicity: A Potential Therapeutic Strategy for Preeclampsia},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {20},
  doi = {10.1161/jaha.126.050607}
}
Kostenlos starten →